In an adult presenting with acute ischemic stroke, when is dual antiplatelet therapy (DAPT) indicated versus aspirin monotherapy based on stroke severity (NIH Stroke Scale) and high‑risk TIA (ABCD2 score)?

DAPT vs Monotherapy in Acute Stroke

For minor noncardioembolic ischemic stroke (NIHSS ≤3) or high-risk TIA (ABCD2 ≥4), initiate dual antiplatelet therapy (aspirin plus clopidogrel) within 12-24 hours and continue for 21-90 days, then transition to single antiplatelet therapy. 1

Treatment Algorithm by Stroke Severity and Risk

Minor Stroke (NIHSS ≤3) or High-Risk TIA (ABCD2 ≥4)

• Start DAPT (aspirin + clopidogrel) within 12-24 hours (ideally) and no later than 7 days from symptom onset 1
• Continue for 21-90 days, then switch to single antiplatelet therapy 1
• This reduces recurrent ischemic stroke risk by approximately 32% (RR 0.68) 2
• The greatest benefit occurs in the first week after initiation, with diminishing efficacy thereafter 3

Minor to Moderate Stroke (NIHSS ≤5) or Very High-Risk TIA (ABCD2 ≥6)

• DAPT with ticagrelor plus aspirin for 30 days may be considered if presenting within 24 hours 1
• This option also applies to symptomatic intracranial or extracranial stenosis ≥30% 1
• Note: Ticagrelor-based DAPT has a 94% probability of being superior to other regimens for minor stroke 4

Moderate to Severe Stroke (NIHSS >5)

• Use single antiplatelet therapy (aspirin 50-325 mg daily, clopidogrel 75 mg, or aspirin-dipyridamole) 1
• DAPT is not indicated for moderate-severe strokes outside the specific criteria above

Critical Timing Considerations

The benefit-to-risk ratio of DAPT is time-dependent:

• Week 1: Maximum ischemic benefit (benefit-to-risk ratio 12.87) 3
• Weeks 2-4: Diminishing efficacy 3
• Beyond 90 days: No ischemic benefit, but increased bleeding risk (RR 2.42 for major bleeding) 2

Do not continue DAPT beyond 90 days - this is associated with excess hemorrhage without additional stroke prevention benefit 1

Bleeding Risk Trade-offs

DAPT increases bleeding complications but with acceptable risk in the short term:

• Major bleeding increases approximately 2-fold (RR 1.88-2.19) 2, 5
• Hemorrhagic stroke risk doubles (RR 2.08) 5
• However, no increase in mortality 5
• Bleeding risk is highest in the first 2 weeks 3

The number needed to treat is 40-58 to prevent one recurrent stroke, while the number needed to harm is 284-330 for major bleeding 4, indicating favorable net clinical benefit.

Common Pitfalls to Avoid

1. Don't use ABCD2 score alone for triage - it has limited sensitivity and may miss high-risk patients 1. The score was developed before DAPT era and overestimates post-treatment stroke risk 6

2. Don't delay DAPT initiation - benefit is concentrated in the first week, with the greatest risk reduction when started within 24 hours 7, 3

3. Don't continue DAPT indefinitely - beyond 90 days, bleeding risk outweighs any ischemic benefit 1, 2

4. Don't use DAPT for cardioembolic stroke - these recommendations apply only to noncardioembolic stroke; patients with atrial fibrillation require anticoagulation 8

5. Don't forget the loading dose - DAPT initiated with a loading dose shows greater efficacy 7

Special Considerations

• Patients already on aspirin: Effectiveness of dose escalation or switching agents is not well established 1
• Presence of acute infarct on imaging: Even with symptom resolution (TIA), patients with visible infarct have 3-4 times higher early stroke risk and may benefit more from DAPT 6
• Recent evidence extends DAPT benefits to strokes with NIHSS up to 15 in some contexts 7, though guideline recommendations remain conservative at NIHSS ≤5